title: Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.
abstract: OBJECTIVE
  To evaluate the prognostic significance of plasma N-terminal pro-atrial natriuretic factor (1-98) concentrations measured in the subacute phase after acute myocardial infarction, and to compare the predictive value of measurement of N-terminal pro-atrial natriuretic factor (1-98) with the measurement of atrial natriuretic factor (99-126) and with clinical assessment of the degree of heart failure.
  
  
  METHODS
  Prospective observational.
  
  
  METHODS
  Norwegian central hospital.
  
  
  METHODS
  139 patients (mean (SD) age 66.9 (11.1) years, 71.2% males) with acute myocardial infarction. Patients in cardiogenic shock or with severe heart failure (New York Heart Association class IV) were excluded.
  
  
  METHODS
  Cardiovascular death within 12 months.
  
  
  RESULTS
  During the follow up period 15 patients died. In a univariate Cox proportional hazards model N-terminal pro-atrial natriuretic factor (1-98) was significantly related to mortality (p = 0.0003). In a multivariate model the prognostic value of N-terminal pro-atrial natriuretic factor (1-98) was better than that of atrial natriuretic factor (99-126) and clinical assessment of heart failure (N-terminal pro-atrial natriuretic factor (1-98), p = 0.0003; atrial natriuretic factor (99-126), p = 0.4513; heart failure, p = 0.0719). The odds ratio estimate of patients in whom plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) were greater than 2000 pmol/l was 25 (95% confidence interval 2.8-225.0) compared with patients with plasma concentrations less than 1000 pmol/l.
  
  
  CONCLUSIONS
  These results suggest that determination of plasma N-terminal pro-atrial natriuretic factor (1-98) in the subacute phase of myocardial infarction may provide clinically relevant prognostic information that is superior to that obtained from atrial natriuretic factor (99-126) measurements and clinical evaluation.
authors.affiliation: Medical Department, Central Hospital, Norway.
authors.forename: T
authors.initials: T
authors.lastname: Omland
authors.forename: V V
authors.initials: VV
authors.lastname: Bonarjee
authors.forename: D W
authors.initials: DW
authors.lastname: Nilsen
authors.forename: J A
authors.initials: JA
authors.lastname: Sundsfjord
authors.forename: R T
authors.initials: RT
authors.lastname: Lie
authors.forename: G
authors.initials: G
authors.lastname: Thibault
authors.forename: K
authors.initials: K
authors.lastname: Dickstein
mesh_terms: D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011498:Protein Precursors / Q000097:blood*
chemical_list: D010446:Peptide Fragments; D011498:Protein Precursors; C055659:atrial natriuretic factor prohormone (1-98); D009320:Atrial Natriuretic Factor